

## References

- Abdelhafiz A et al. *J Diabetes Nurs.* 2016;20:330–331
- Abdelhafiz AH et al. *Aging Dis.* 2015;6:156–167
- Barron E et al. *Lancet Diabetes Endocrinol* 2020; 8: 813–822
- Bunn F et al. *Systematic reviews.* 2016;5:5
- Centers for Disease Control and Prevention. *What you can do if you are at higher risk of severe illness from COVID-19.* 2020. Available at: <https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/what-you-can-do.html> (accessed November 2021)
- Clegg A et al. *Age Ageing* 2016;45:353–360
- De Lepeleire J et al. *Br J Gen Pract* 2009;59:e177–82
- Davies MJ et al. *Diabetes Care* 2018;41:2669–2701
- Diabetes.co.uk. *Diabetes and the elderly.* Available at: <https://www.diabetes.co.uk/diabetes-and-the-elderly.html> (accessed November 2021)
- Diabetes UK (2019) *Us, diabetes and a lot of facts and stats.* Available at: <https://www.diabetes.org.uk/resources-s3/2019-11/facts-stats-update-oct-2019.pdf> (accessed November 2021)
- Fadini GP et al. *J Endocrinol Invest.* 2020;43(6):867–869
- Gale CR et al. *Age Ageing.* 2015;44:162–165
- Hahr AJ and Molitch ME. *Clin Diabetes Endocrinol* 2015;1:2
- Jaap AJ et al. *Diabet Med.* 1998;15:398–401
- Kalra S et al. *Indian J Endocrinol Metab* 2013;17:819–834
- Kamel HK, Iqbal MA. *Arch Intern Med* 2001;161:1459–60
- Mendola ND et al. *NCHS data brief.* 2018;319:1–8
- Merchant RA et al. *J Nutr Health Aging* 2021;25:405–409
- Mitnitski A, et al. *JAGS.* 2005; 53: 2184–2189
- Morley JE et al. *J Am Med Dir Assoc.* 2013;14:392–397
- NHS Digital. *Diabetes prevention programme, 2017–18. Diagnoses and demographics.* *NHS Digital, 2019.* Available at: [files.digital.nhs.uk/1B/D8C0E4/NDA\\_DPP\\_MainReport\\_1718\\_1.1.pdf](files.digital.nhs.uk/1B/D8C0E4/NDA_DPP_MainReport_1718_1.1.pdf) (accessed November 2021)
- NHS. *Quality and Outcomes Framework guidance for 2021/22.* Available at: <https://www.england.nhs.uk/wp-content/uploads/2021/03/B0456-update-on-quality-outcomes-framework-changes-for-21-22-.pdf> (accessed November 2021)
- NICE. *British National Formulary.* Available at: <https://bnf.nice.org.uk/treatment-summary/type-2-diabetes.html> (accessed November 2021)
- NICE. *New indicators added to the NICE indicator menu for general practice. October 2018.* Available at: <https://www.nice.org.uk/Media/Default/Standards-and-indicators/indicators-general-practice.pdf> (Accessed November 2021).
- Public Health England. *Disparities in the risk and outcomes from COVID-19.* 2020.
- Ogawa W, Sakaguchi K. *J Diabetes Investig* 2016;7:135–138.
- Retnakaran R et al. *Diabetes* 2006;55:1832–1839
- Shumway-Cook A et al. *Physical Therapy* 2000;80:896–903
- Singh AK, Khunti K. *Diabetes Res Clin Pract* 2020;165:108266
- Spiegelhalter D. *BMJ* 2020;370:m3259.
- Stow D et al. *BMC Med* 2018;16: 171
- Strain WD et al. *Diabet Med.* 2018;35:838–845
- Strain WD et al. *Diabetes Therapy* 2021;12:1227–1247
- Stratton IM et al. *BMJ* 2000;321:405–412
- The OpenSAFELY Collaborative et al. *medRxiv* 2020
- Trajenta (linagliptin) *Summary of Product Characteristics.* Available at: [www.medicines.org.uk](http://www.medicines.org.uk) (accessed November 2021)
- Zhu L et al. *Cell Metabolism* 2020;31:1